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Immune suppression after liver transplant for malignancy, such as hepatocellular carcinoma and end stage liver disease is 
done using immunosuppressant drugs like tacrolimus. As the immune system in children is not fully developed, combining 
immunosuppressants like glucocorticoids influence the efficacy and reduce the chances of transplant rejection, particularly 
in patients with gene polymorphism. However, whether interaction between glucocorticoid and tacrolimus is associated with 
CYP3A, MDR1, and PXR gene polymorphisms, remains unclear. Here, we explored correlations of synergistic effect of 
glucocorticoids on tacrolimus with CYP3A, MDR1 and PXR gene polymorphisms in pediatric patients receiving liver 
transplantation for malignancy and chronic liver disease. A total of 340 eligible children were divided into glucocorticoid 
(+) (n=148) and glucocorticoid () groups (n=192). They were given tacrolimus + mycophenolate mofetil, based on which 
glucocorticoid (+) group took prednisone acetate tablets for ≥12 months. The blood trough concentration of tacrolimus was 
detected by chemiluminescence microparticle immunoassay 1, 3, 6 and 12 months after medication, and blood drug 
concentration corrected by daily concentration/daily dose (C0/D) was calculated. CYP3A, MDR1 and PXR gene 
polymorphisms were analyzed using PCR-RFLP. GG, AG and AA genotypes of CYP3A were observed in 130, 166 and 44 
cases, respectively. CC, CT and TT genotypes of MDR1 were found in 152, 142 and 46 cases, respectively. There were 252, 
74 and 14 cases of WW, WM and MM genotypes of PXR, respectively. The distribution frequencies of GG and AG+AA 
genotypes had significant differences between the two groups. One month after medication, C0/D of tacrolimus of GG 
genotype in glucocorticoid (+) group significantly exceeded that of glucocorticoid () group. C0/D was significantly higher 
in glucocorticoid (+) group with AG+AA genotype1, 3, 6 and 12 months after medication (P <0.05). 
Keywords: Immunosuppressant 
Immunosuppressants can suppress the proliferation 
and function of cells related to the immune response, 
such as T cells, B cells and other macrophages, 
thereby weakening the antibody immune response
1,2
. 
At present, liver, kidney, skin and heart 
transplantation have been quite successful, among 
which kidney and liver transplantation are applied 
most widely in clinical practice
3
. In children, living 
donor liver transplantation si considered as one of the 
effective and safe therapeutic regimen for malignancy 




Currently, tacrolimus is mainly used as the first-
line immunosuppressant after liver transplantation in 
adults and children
5
. However, tacrolimus needs to be 
taken for a long time and has high costs, with a short 
therapeutic window and large individual differences. 
In existing reports of liver transplantation centers in 
China, the dosage of tacrolimus and effective range  
of blood drug concentration after liver transplantation 
in children are inconsistent
6
. Compared with adult 
recipients, the immune system of child liver  
transplant recipients has not fully developed. Gene 
polymorphisms have been shown to be responsible  
for large individual differences in tacrolimus 
pharmacokinetics
7,8
. Tacrolimus is mainly 
metabolized by cytochrome P450 3A (CYP3A) in the 
liver and intestine
9
, and it is the substrate of  
P-glycoprotein (P-gp) encoded by multidrug 
resistance gene 1 (MDR1)
10
. Human pregnane  
X receptor (PXR), a fat-soluble ligand-dependent 
transcription factor, can affect the metabolic pathways 
of tacrolimus in the liver and intestine through 
regulating the gene expressions of key metabolic 










Glucocorticoid (GC) is an extremely important 
class of regulatory molecules dominantly regulating 
development, growth, metabolism and immune 
function. After liver transplantation for hepatic 
malignancy in children, double or triple anti-rejection 
therapy with tacrolimus + GC and mycophenolate 
mofetil is also an authoritative immunosuppressive 
therapy. GC is the inducer of P-gp and/or CYP3A
11
. 
The combination of GC and P-gp and/or CYP3A 
substrate is known to alter the pharmacokinetic 
characteristics of drugs in patients, thus changing the 
efficacy or side effects
12
. GC can significantly 






the interaction between GC and tacrolimus is 
associated with the gene polymorphisms of CYP3A, 
MDR1 and PXR has not been reported yet. Here, we 
explored the correlations of synergistic effect of 
glucocorticoids on tacrolimus with CYP3A, MDR1 
and PXR gene polymorphisms in pediatric patients 
receiving liver transplantation. 
 
Materials and methods 
 
Baseline clinical data 
A total of 340 pediatric patients who underwent 
liver transplantation for malignancy and end stage 
liver disease in our hospital from June 2015 to June 
2020 and received tacrolimus maintenance therapy 
after operation were selected. Inclusion criteria:  
(i) Patients undergoing anti-rejection therapy with 
tacrolimus + mycophenolate mofetil after organ 
transplantation; (ii) aged <14 years old; (iii) with stable 
liver function (level of alanine aminotransferase (ALT) 
or aspartate aminotransferase (AST) <3 times that of 
the upper limit of normal range); (iv) without using 
other drugs affecting CYP3A enzyme and P-gp  
(e.g. diltiazem, ketoconazole, berberine and 
bifendate); (v) with complete clinical data; and  
(vi) those who took GC for >12 months. Exclusion 
criteria: (i) Patients complicated with fungal infection; 
(ii) with ALT or AST level>5 times that of the upper 
limit of normal range; (iii) with renal creatinine 
clearance rate <20 mL/min; (iv) complication with 
severe blood diseases or complications. The research 
protocol was approved by the Medical Ethics 
Committee of our hospital, and the guardians of all 
children were informed and signed the informed 
consent. They were divided into GC (+) and GC () 
groups according to whether GC prednisone acetate 
was combined. 
Treatment methods 
In GC () group, the patients were treated with 
routine symptomatic treatment: Tacrolimus Capsules 
(Astellas Pharma Inc., Ireland) (0.5-4.5 mg, po, bid) + 
Mycophenolate Mofetil Tablets (Shanghai Roche 
Pharmaceutical Co., Ltd., China) (0.5-1 g, po, bid). 
Based on the above treatment, the patients in GC (+) 
group were given prednisone acetate tablets (Zhejiang 
Xianju Pharmaceutical Co., Ltd., China) (5-30 mg, 
po, qd). The treatment lasted for >12 months in both 
groups. 
 
Measurement of blood concentration of tacrolimus 
Before medication and at least 1 week after the 
dose of tacrolimus was adjusted or prednisone acetate 
tablets were combined, 5 mL of fasting venous blood 
was drawn on the next day morning. Then the blood 
trough concentration of tacrolimus in patients was 
detected within 3 hours by chemiluminescence 
microparticle immunoassay using Architect i1000 
automatic immunoassay analyzer (Abbott, USA) 0, 1, 
3, 6 and 12 months after medication, and the blood 
drug concentration corrected by daily dose, i.e. blood 
trough concentration/daily dose [C0/D, (ng/mL)/(mg/d)], 
at each time point was calculated. 
 
Analysis of YP3A, MDR1 and PXR gene polymorphisms by 
PCR-RFLP 
The peripheral blood DNA was extracted using 
Wizard DNA extraction kit (Promega, USA) 
according to the manufacturer’s instructions. Upstream 
primer of CYP3A 6986: 5'-CATGACTTAGTAGAC 
AGATGAC-3', downstream primer: 5'-GGTCCAAA 
CAGGGAAGAAATA-3'.Upstream primer of MDR1 
exon 21 G2677A: 5'-TACCCATCATTGCAATAGC 
AG-3', downstream primer: 5'-TTTAGTTTTGACTC 
ACCTTTCTAG-3'. Upstream primer of PXR rs3842689: 
5'AATCACCACAGGAGAAGC-3', downstream primer: 
5'-AAAAGGAATCAGGACTGAGT-3'. PCR was 
performed as follows: pre-denaturation at 98°C for 3 
min, (denaturation at 98°C for 15 s, annealing at 55°C 
for 30 s, and extension at 72°C for 40 s) × 34 cycles, 
and extension at 72°C for 5 min finally.The PCR 
products were subjected to 1.5% agarose gel 
electrophoresis. Then the gel was recycled and 
identified by enzyme digestion on water bath at 37°C 
for 2 h, and the results were determined.  
 
Statistical analysis 
SPSS 20.0 software was used for statistical 
analysis. Normality analysis was performed using 
the Kolmogorov-Smirnov test. The parametric 
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method was adopted for the data in line with normal 
distribution and homogeneity of variance; otherwise 
the non-parametric method was utilized. Quantitative 
data in line with normal distribution were expressed 
as (mean ± SD), and the independent-samples t test 
was conducted for intergroup comparisons. 
Quantitative data not conforming to normal 
distribution were expressed as median (P25, P75), and 
the Mann-Whitney U test was carried out for 
intergroup comparisons. Numerical data were 
expressed as rate, and the χ
2
 test or Fisher’s exact 
test was used for intergroup comparisons. Whether 
the distribution of CYP3A, MDR1 and PXR 
genotypes conformed to Hardy-Weinberg 
equilibrium was evaluated by the χ
2
 test. The change 
trend of C0/D of tacrolimus with time and the effect 
of GC on C0/D of tacrolimus were explored using 
repeated measures analysis of variance. The 
differences in C0/D were detected through analysis 
of covariance among patients with different 
genotypes in the two groups. C0/D of tacrolimus and 
red blood cell (RBC) count 0 month after medication 
were used as covariates in repeated measures 
analysis of variance and analysis of covariance, and 
C0/D was converted into natural logarithm ln C0/D. 
Analysis of variance was performed after lnC0/D 
conformed to normal distribution and homogeneity 




Baseline clinical data 
Among the 340 patients, there were 148 cases in 
GC (+) group, including 102 boys and 46 girls with an 
average age of (10.41±2.91) years old. There were 
192 cases in GC () group, including 130 boys and 62 
girls with an average age of (10.62±2.94) years old. 
The two groups had similar gender, age, body mass, 
BMI, time of transplantation, serum creatinine, ALT, 
AST and hemoglobin levels(P >0.05), but significantly 
different RBC counts (P <0.001) (Table 1). 
 
Distribution of CYP3A, MDR1 and PXR genotypes 
GG, AG and AA genotypes of CYP3A were 
observed in 130, 166 and 44 cases, respectively. CC, 
CT and TT genotypes of MDR1 were found in 152, 
142 and 46 cases, respectively. Moreover, there were 
252, 74 and 14 cases of WW, WM and MM 
genotypes of PXR, respectively. They all conformed 
to Hardy-Weinberg equilibrium (P >0.05). 
GC (+) and GC () groups had significantly 
different distributions of CYP3A GG and AG+AA 
genotypes (P <0.001), different distributions of 
MDR1 CC and CT+TT genotypes (P=0.005), but 
similar distribution of PXR WW and WM+MM 
genotypes (P >0.05) (Table 1). 
 
Effects of GC on C0/D of tacrolimus 
Concentration/daily dose (C0/D) of tacrolimus was 
significantly higher in GC (+) group than that of  
Table 1 — Baseline clinical data of selected patients and Distribution of CYP3A, MDR1 and PXR genotypes 
 GC (+) group (n=148) GC (-) group (n=192) χ2/t/U P 
Clinical data     
Male/female (case) 102/46 130/62 0.057 0.812 
Age (year) 10.41±2.91 10.62±2.94 0.656 0.512 
Body mass (kg) 33.09±4.61 33.45±4.69 0.707 0.480 
BMI (kg/m2) 19.78±2.18 20.02±2.19 1.004 0.316 
Serum creatinine [median (P25, P75)] 
(μmol/L) 
118.62 (89.23, 150.27) 107.26 (90.23, 143.89) 0.375 0.643 
Transplantation time [median (P25, P75)] 
(month) 
18.00 (6.00, 72.00) 23.50 (12.00, 29.00) 0.984 0.243 
ALT [median (P25, P75)] (U/L) 19.50 (12.00, 29.50) 19.00 (12.00, 27.50) 0.253 0.784 
AST [median (P25, P75)] (U/L) 16.50 (12.00, 20.00) 17.00 (12.00, 21.00) 0.324 0.675 
RBC (×1012L-1) 3.66±0.72 4.00±0.84 3.934 <0.001 
Hemoglobin [median (P25, P75)] (g/L) 113.50 (96.50, 128.50) 123.00 (100.00, 137.50) 1.927 0.074 
Genotypes     
CYP3A   35.817 <0.001 
GG 30 (20.3) 100 (52.1)   
AG+AA 118 (79.7) 92 (47.9)   
MDR1   7.716 0.005 
CC 54 (36.5) 98 (51.0)   
CT+TT 96 (63.5) 94 (49.0)   
PXR   0.179 0.672 
WW 108 (73.0) 144 (75.0)   
WM+MM 40 (27.0) 48 (25.0)   




GC () group 0 month after treatment (P <0.05), 
which were similar at other time points (P >0.05). 
Repeated measures analysis of variance showed that 
the main effect of grouping was significant (P <0.05), 
while the main effect of time and the interactive effect 
of time and grouping were not significant within 1-12 
months (P >0.05). C0/D of tacrolimus was higher in 
GC (+) group than that in GC () group, the change 
trend of C0/D of tacrolimus with time was not 
obvious, and the difference between the two groups 
did not change with time (Table 2). 
 
Effects of CYP3A, MDR1 and PXR gene polymorphisms on 
synergistic effect of GC 
One month after medication, C0/D of tacrolimus 
was significantly higher in patients with GG genotype 
in GC (+) group than that in patients with the same 
genotype in GC () group (P <0.05). C0/D of patients 
with GG genotype had nosignificant difference 
between the two groups 3, 6 and 12 months after 
medication (P >0.05). C0/D was significantly higher 
in patients with AG+AA genotype in GC (+) group 
than that in patients with the same genotype in GC () 
group (P <0.05). No statistically significant 
differences were found in C0/D of patients with 
various genotypes of MDR1 and PXR at each time 
point (P >0.05) (Table 3).  
 
Discussion 
After entering the human body, 83.2% of 
tacrolimus binds RBCs
13
. RBC count in GC (+) group 
was lower, so fewer RBCs bound to tacrolimus, 
which may be responsible for the markedly lower 
C0/D of tacrolimus in GC (+) group than that in GC 
() group 0 month after medication. 
 
In this study, GC effectively raised C0/D of 
tacrolimus, being consistent with a previous 
literature
14
. The change in trend of C0/D of tacrolimus 
with time was not obvious within 1-12 months after 
taking GC (main effect of time, P >0.05). CYP3A 
enzyme can metabolize midazolam (with similar 
metabolic characteristics to tacrolimus in vivo) into 1'-
hydroxy midazolam. After GC is used, the 
bioavailability of midazolam is greatly improved, 
Table 3 — Concentration/Dose (C0/D) values of tacrolimus in patients with different genotypes after select periods of treatment in 
MDR1 and PXR groups [median (P25, P27), (ng/mL)/(mg/d)] 
Genotype Group After 0 month After 1 month After 3 months After 6 months After 12 months 
GG GC (+) group (n=30) 1.08 (0.86,2.36) 2.55 (1.44,3.83) 2.21 (1.34,3.23) 2.36 (1.59,4.17) 2.04 (1.88,3.11) 
GC () group (n=100) 2.21 (1.53,3.23) 2.30 (1.54,3.31) 2.26 (1.52,2.69) 2.37 (1.66,3.24) 2.35 (1.59,3.17) 
F  5.718 0.836 1.092 0.165 
P  0.019 0.403 0.301 0.718 
AG+AA GC (+) group (n=118) 0.67 (0.51,0.89) 1.67 (1.36,2.14) 1.86 (1.32,2.28) 1.89 (1.32,2.41) 1.79 (1.36,2.50) 
GC () group (n=92) 1.19 (0.75,1.60) 1.19 (0.84,1.89) 1.22 (0.91,1.78) 1.42 (0.97,1.69) 1.33 (0.89,1.79) 
F  13.487 20.084 17.265 16.598 
P  <0.001 <0.001 <0.001 <0.001 
CC GC (+) group (n=54) 1.23 (0.83,2.45) 2.45 (1.26,3.56) 2.19 (1.18,3.32) 2.37 (1.51,4.12) 2.27 (1.56,3.23) 
GC () group (n=98) 2.08 (1.46,3.34) 2.40 (1.18,3.56) 2.23 (1.43,2.64) 2.37 (1.61,3.29) 2.32 (1.45,3.45) 
F  0.876 0.756 0.567 0.892 
P  0.226 0.376 0.584 0.205 
CT+TT GC (+) group (n=96) 0.75 (0.49,0.92) 1.61 (1.31,2.18) 1.56 (1.19,2.34) 1.69 (1.17,2.21) 1.49 (1.31,2.60) 
GC () group (n=94) 1.06 (0.69,1.65) 1.56 (1.14,2.03) 1.53 (1.01,2.09) 1.62 (1.07,1.98) 1.53 (1.29,2.54) 
F  0.943 0.805 0.683 0.298 
P  0.122 0.336 0.435 0.847 
MM GC (+) group (n=108) 1.12 (0.82,2.39) 2.36 (1.14,2.84) 2.22 (1.24,2.73) 2.35 (1.41,3.38) 2.19 (1.18,2.91) 
GC () group (n=144) 2.15 (1.45,3.45) 2.33 (1.24,2.86) 2.25 (1.32,2.62) 2.38 (1.46,3.45) 2.22 (1.19,3.02) 
F  0.764 0.647 0.924 0.671 
P  0.432 0.354 0.112 0.329 
WM+MM GC (+) group (n=40) 0.69 (0.52,0.96) 1.54 (1.12,2.45) 1.56 (1.12,2.45) 1.59 (1.12,2.67) 1.48 (1.17,2.70) 
GC () group (n=48) 1.15 (0.78,1.74) 1.48 (0.89,1.99) 1.54 (0.99,2.38) 1.52 (1.07,2.71) 1.46 (1.12,2.83) 
F  0.764 0.786 0.928 1.023 
P  0.337 0.342 0.194 0.098 
Table 2 — ‎Concentration/Dose (C0/D) values of tacrolimus after 
select periods of treatment in CYP3A group [median (P25, P27), 
(ng/mL)/(mg/d)] 
 GC (+) group 
(n=148) 
GC () group 
(n=192) 
U* P# 
After 0 month 0.73 (0.54, 1.04) 1.59 (0.95, 2.43) 6.098 <0.001 
After 1 month 1.72 (1.37, 2.40) 1.65 (1.00, 2.63) 0.894 0.113 
After 3 months 1.86 (1.32, 2.33) 1.77 (1.09, 2.43) 0.802 0.258 
After 6 months 1.92 (1.37, 2.55) 1.74 (1.24, 2.51) 1.203 0.232 
After 12 months 1.89 (1.50, 2.54) 1.74 (1.30, 2.72) 0.903 0.386 
F# 19.293   
P# <0.001   
[*Mann-Whitney U test; #repeated measures analysis of variance] 
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proving that GC can inhibit the metabolic activity of 
CYP3A enzyme
15
. Both GC and tacrolimus are 
substrates of CYP3A enzyme. GC has higher affinity 
for CYP3A enzyme than tacrolimus. As a result, the 
number of CYP3A enzymes metabolizing tacrolimus 





CYP3A GG genotype can encode abnormal 
mRNAs, and make CYP3A5 enzymes unable to be 
expressed normally, leading to the decline in the 
metabolic rate of tacrolimus. The patients with GG 
genotype are low-dose tacrolimus group. On the 
contrary, normal mRNAs can be produced and a large 
number of functional CYP3A5 enzymes are expressed 
in patients with AG+AA genotype, thus increasing the 
metabolic rate of tacrolimus, so patients with AG+AA 
genotype are high-dose tacrolimus group
17
. Herein, 
when tacrolimus was combined with GC, the effects 
of different CYP3A genotypes on C0/D of tacrolimus 
differ greatly. Patients with CYP3A AG+AA 
genotype were more sensitive to the synergistic effect 
of GC (at 1-12 months after medication). GC 
markedly raised C0/D of tacrolimus in patients with 
CYP3A AG+AA genotype, being consistent with the 
results of a prospective study
18
 in which, however, 
patients with CYP3A GG genotype were not studied. 
In another study, the dosage of tacrolimus in patients 
with CYP3A GA genotype in GC group declined by 
36% compared with that in control group, but it was 
not compared in patients with CYP3A GG and AA 
genotypes
19
. The metabolism of CYP3A enzymes is 
affected by substrates, inhibitors and number of 
enzymes. The individual differences caused by the 
same inhibitor and substrate are largely determined by 
the number of metabolic enzymes
18
. More CYP3A5 
enzymes can be expressed in the case of CYP3A5 
AG+AA genotype
20
. Patients with AG+AA genotype 
are more sensitive to GC, while GC has no significant 
effect on patients with GG genotype, but its 
mechanism has not been clarified yet. Probably, the 
activity of CYP3A5 enzymes is high and can be 
competitively inhibited by GC in patients with 
CYP3A expressed genotype, thus obviously raising 
the blood concentration of tacrolimus. Notably, the 
effects of CYP3A genotypes on drug interaction of 
tacrolimus are inconsistent. For example, the 
tacrolimus clearance rate is higher in patients with 
CYP3A AG+AA genotype when amlodipine is 
combined with tacrolimus
21
. C0/D of tacrolimus is 
higher in patients with CYP3A AG+AA genotype 
when diltiazem is combined with tacrolimus, while it 
is higher in patients with CYP3A GG genotype in the 
case of combination of ketoconazole and tacrolimus
22
. 
The results of this study are inapplicable to other 
drugs affecting the metabolism of tacrolimus, and the 
mechanism still needs further research. 
 
Conclusion 
Results of the present study have demonstrated that 
glucocorticoids (GC) could singnificantly increase the 
concentration/daily dose (C0/D) of tacrolimus in 
patients reveiving liver transplantation for malignancy 
and chronic liver disease with CYP3A AG+AA 
genotype, but not in patients with GG genotype. 
Hence, it is recommended that when GC is used as the 
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